Spinal Muscular Atrophy Market Size, Share & Trend Analysis, Epidemiology and Market Forecast 2028

March 18 12:50 2020
Spinal Muscular Atrophy Market Size, Share & Trend Analysis, Epidemiology and Market Forecast 2028

Delveinsight Business Research
DelveInsight’s “Spinal Muscular Atrophy Market Insights, Epidemiology, and Market Forecast 2028” report delivers an in-depth understanding of the Spinal Muscular Atrophy, historical and forecasted epidemiology as well as the Spinal Muscular Atrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Spinal Muscular Atrophy market report provides in-depth current treatment practices, emerging drugs, Spinal Muscular Atrophy market share of the individual therapies, current and forecasted Spinal Muscular Atrophy Market Size from 2017 to 2028 segmented by seven major markets. 

The report also provides comprehensive current Spinal Muscular Atrophy treatment practice & algorithm, market drivers, market barriers and unmet medical needs to cater best of the opportunities and assessments underlying potential of Spinal Muscular Atrophy market.

 

Spinal Muscular Atrophy market key facts

  • In 2017, the total prevalent population of Spinal Muscular Atrophy (SMA) in 7 major markets was approximately 19,343 cases. 

  • The diagnosed prevalent cases of Spinal Muscular Atrophy in the United States were found to be 11,733 in 2017. 

  • The available literature suggests both males and females are equally affected with SMA.

  • There are many types of spinal muscular atrophy (SMA Type 0, I, II, III and IV) that are caused by changes in the same genes. The types differ in age of onset and severity of muscle weakness; however, there is overlap between the types.

Request for Sample Pages: https://www.delveinsight.com/report-store/spinal-muscular-atrophy-sma-market-insight-epidemiology-and-market-forecast

 

Key benefits of Spinal Muscular Atrophy Market report

  • Spinal Muscular Atrophy market report provides an in-depth analysis of Spinal Muscular Atrophy market, size, share, trend analysis  epidemiology and market forecast till 2028, in 7 major market i.e. EU5 (Germany, italy, Spain, France and the UK), Japan, and the United States.

  • The Spinal Muscular Atrophy market report covers Spinal Muscular Atrophy current treatment practices, emerging drugs, market share of the individual therapies.

  • The Spinal Muscular Atrophy market report covers the marketed and emerging therapies of Spinal Muscular Atrophy.

  • The Spinal Muscular Atrophy market report helps business understand the Spinal Muscular Atrophy market trends that will shape and drive the Spinal Muscular Atrophy market in upcoming years.

Spinal Muscular Atrophy Market

The Spinal Muscular Atrophy market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Spinal Muscular Atrophy market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 

Spinal Muscular Atrophy market segment gives a thorough detail of Spinal Muscular Atrophy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. 

 

 

Spinal Muscular Atrophy Epidemiology

The Spinal Muscular Atrophy epidemiology division provides insights about historical and current Spinal Muscular Atrophy patient pool and forecasted trends for every seven major countries. 

The disease epidemiology covered in the report provides historical as well as forecasted Spinal Muscular Atrophy epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2028. 

The epidemiology segment also provides the Spinal Muscular Atrophy epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan along with diagnosed patient pools and their trends with assumptions undertaken.

The launch of the emerging therapies is expected to significantly impact Spinal Muscular Atrophy treatment scenario in the upcoming years. Some of the drugs covered in the report include Risdiplam, Reldesemtiv, Branaplam,  Amifampridine Phosphate, and many more. 

The key players in Spinal Muscular Atrophy market include Novartis, PTC Therapeutics, Hoffmann-La Roche, Cytokinetics, Astellas, Catalyst Pharmaceuticals and many others.

 

Table of contents

1. Key Insights

2. Executive Summary of Spinal Muscular Atrophy

3. Spinal Muscular Atrophy Competitive Intelligence Analysis

4. Spinal Muscular Atrophy Market Overview at a Glance

5. Spinal Muscular Atrophy Disease Background and Overview

6. Spinal Muscular Atrophy Patient Journey

7. Spinal Muscular Atrophy Epidemiology and Patient Population

8. Spinal Muscular Atrophy Treatment Algorithm, Current Treatment, and Medical Practices

9. Spinal Muscular Atrophy Unmet Needs

10. Key Endpoints of Spinal Muscular Atrophy Treatment

11. Spinal Muscular Atrophy Marketed Products

12. Spinal Muscular Atrophy Emerging Therapies

13. Spinal Muscular Atrophy Seven Major Market Analysis

14. Attribute analysis

15. Spinal Muscular Atrophy Market Outlook (in 7 major markets)

16. Access and Reimbursement Overview of Spinal Muscular Atrophy

17. KOL Views on Spinal Muscular Atrophy market.

18. Spinal Muscular Atrophy Market Drivers

19. Spinal Muscular Atrophy Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Related Reports:-

Spinal Muscular Atrophy (SMA) Epidemiology Forecast to 2030

DelveInsight’s ‘Spinal Muscular Atrophy Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Spinal Muscular Atrophy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

 

Spinal Muscular Atrophy (SMA) Pipeline Insights, 2020

“Spinal Muscular Atrophy Pipeline Insight, 2020” report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Spinal Muscular Atrophy market. A detailed picture of the Spinal Muscular Atrophy pipeline landscape is provided, which includes the disease overview and Spinal Muscular Atrophy treatment guidelines. 

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/